During the last session, Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s traded shares were 0.65 million, with the beta value of the company hitting 1.25. At the end of the trading day, the stock’s price was $1.55, reflecting an intraday gain of 19.23% or $0.25. The 52-week high for the CTXR share is $26.75, that puts it down -1625.81 from that peak though still a striking 21.94% gain since the share price plummeted to a 52-week low of $1.21. The company’s market capitalization is $13.32M, and the average intraday trading volume over the past 10 days was 0.13 million shares, and the average trade volume was 143.15K shares over the past three months.
Citius Pharmaceuticals Inc (CTXR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CTXR has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 1.3.
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Citius Pharmaceuticals Inc (CTXR) registered a 19.23% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 19.23% in intraday trading to $1.55, hitting a weekly high. The stock’s 5-day price performance is 1.97%, and it has moved by -5.49% in 30 days. Based on these gigs, the overall price performance for the year is -92.26%. The short interest in Citius Pharmaceuticals Inc (NASDAQ:CTXR) is 0.52 million shares and it means that shorts have 2.93 day(s) to cover.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.78M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 3.95M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 20.90%. While earnings are projected to return 122.61% in 2025.
CTXR Dividends
Citius Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Feb-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Citius Pharmaceuticals Inc insiders own 5.74% of total outstanding shares while institutional holders control 7.97%, with the float percentage being 8.45%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 34.0 institutions own stock in it. As of 2024-06-30, the company held over 10.16 million shares (or 6.3845% of all shares), a total value of $5.93 million in shares.
The next largest institutional holding, with 6.33 million shares, is of VANGUARD GROUP INC’s that is approximately 3.9776% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.69 million.
Also, the Mutual Funds coming in first place with the largest holdings of Citius Pharmaceuticals Inc (CTXR) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 165.58 shares. This amounts to just over 1.93 percent of the company’s overall shares, with a $0.26 million market value. The same data shows that the other fund manager holds slightly less at 78.31, or about 0.91% of the stock, which is worth about $0.12 million.
